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Abstract
Background: Helminth infections, common in low- income countries, may protect 
against allergy- related disease. Early exposure may be a key. In the Entebbe Mother 
and Baby Study, treating helminths during pregnancy resulted in increased eczema 
rates in early childhood. We followed the cohort to determine whether this translated 
to increased asthma rates at school age.
Methods: This randomized, double- blind, placebo- controlled trial, conducted in Entebbe, 
Uganda, had three interventions. During pregnancy, women were randomized, simulta-
neously, to albendazole vs placebo and to praziquantel vs placebo. Their children were 
independently randomized to quarterly albendazole vs placebo from age 15 months to 
5 years. We here report follow- up to age 9 years. Primary outcomes at 9 years were 
recent reported wheeze, skin prick test positivity (SPT) to common allergens and 
allergen- specific IgE positivity to dust mite or cockroach. Secondary outcomes were 
doctor- diagnosed asthma and eczema rates between 5 and 9 years, recent eczema, rhi-
nitis and urticaria at 9 years, and SPT and IgE responses to individual allergens.
Results: 2507 pregnant women were enrolled; 1215 children were seen at age nine, of 
whom 1188 are included in this analysis. Reported wheeze was rare at 9 years (3.7%) 
while SPT positivity (25.0%) and IgE positivity (44.1%) were common. There was no 
evidence of a treatment effect for any of the three interventions on any of the primary 
outcomes.
Conclusions: Prenatal and early- life treatment of helminths, in the absence of change 
in other exposures, is unlikely to increase the risk of atopic diseases later in childhood 
in this tropical, low- income setting.
K E Y W O R D S
albendazole, asthma, atopy, eczema, helminth, IgE, praziquantel, prenatal, school age, wheeze
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1  | INTRODUCTION
Allergy- related diseases (ARD) such as asthma, eczema and rhinitis 
are commoner in high- income countries (HICs) than in low- or middle- 
income countries (LMICs), but their prevalence is increasing in the 
latter, where consequences can be more severe because of limited 
access to diagnosis, care and necessary treatment.1
Understanding exposures that “protect” against ARD in LMICs 
is important—for public health, and to provide insights into possi-
ble interventions for those at risk of ARD. Helminth infections are 
highly prevalent in LMICs, and immune responses to helminths and 
allergens are closely related. IgE and related effector mechanisms 
are likely to have evolved to protect mammals from helminths and 
ectoparasites,2 but parasitic helminths must survive for decades 
in their hosts, and have evolved a myriad of mechanisms to evade 
or suppress the host immune response.3 Animal models provide 
strong evidence that these mechanisms can protect the host against 
allergy- related outcomes.4
In humans, the picture is more complex. Despite inverse asso-
ciations between helminths and atopy, several trials have shown 
no, or little, effect of anthelmintic treatment on allergy- related 
outcomes.4 One possible explanation is that early- helminth expo-
sure has long- term effects, not mitigated by later treatment. In the 
Entebbe Mother and Baby Study (EMaBS), a randomized, placebo- 
controlled trial of anthelmintic treatment during pregnancy, we 
showed a striking increase in the incidence of infantile eczema fol-
lowing maternal treatment with albendazole in a population with a 
high prevalence of maternal hookworm infection. We also observed 
an increase in eczema among infants of mothers with schistosomia-
sis who were treated with praziquantel.5 This was hailed as the first 
demonstration that treatment during pregnancy influenced ARD in 
the offspring.6
As eczema in early childhood may herald the development of 
asthma at school age, and as eczema and asthma may have a com-
mon link to atopy,7 we followed the EMaBS cohort to find out whether 
the prenatal intervention influenced risk of asthma and other allergy- 
related diseases at age 9 years.
2  | METHODS
2.1 | Study design and participants
The Entebbe Mother and Baby Study (EMaBS) was a factorial ran-
domized, placebo- controlled trial of anthelmintic treatment during 
pregnancy and early childhood conducted in Entebbe, Uganda—a 
semi- urban setting in equatorial East Africa [ISRCTN32849447].8,9 
Healthy pregnant women resident in the study area and planning to 
deliver at Entebbe Hospital, with no evidence of helminth- related 
pathology, were recruited between 2003 and 2005 and randomized 
to two interventions simultaneously1 to receive single- dose albenda-
zole (400 mg) or matching placebo and2 to single- dose praziquantel 
(40 mg/kg) or matching placebo, with all treatments received dur-
ing the second or third trimester of pregnancy. When the offspring 
turned 15 months, they were randomized independently from the 
maternal randomization to a third intervention—quarterly albenda-
zole (200 mg below 2 years of age, 400 mg thereafter) or matching 
placebo—which they received until they turned 5 years, making this 
a (2 × 2)×2 factorial design. The cohort has continued under follow-
 up after completion of the trial interventions. We now report on the 
evaluation of allergy- related clinical outcomes from age 5 to 9 years 
and on prevalence of atopy and allergy- related disease at 9 years, 
undertaken to assess longer term impact of early- life interventions. 
Participants, clinicians and laboratory staff remain blinded to treat-
ment allocation; only the trial statisticians have access to the rand-
omization code.
The study was approved by the Research and Ethics Committee of 
the Uganda Virus Research Institute, the Uganda National Council for 
Science and Technology and the London School of Hygiene & Tropical 
Medicine.
2.2 | Study procedures
Children were reviewed by trained health care providers at the re-
search clinic at scheduled annual visits for clinical information and 
stool examination for helminth infections. Children were addition-
ally seen when they were sick, and all illness events recorded. At age 
nine, each child was assessed for allergy- related conditions and atopy 
by history, examination and skin prick testing (SPT). A blood sample 
was taken for immunological studies, including evaluation of allergen- 
specific immunoglobulin E (asIgE).
Stool samples were examined by the Kato- Katz method for intesti-
nal helminths: two slides from a single sample were examined at each 
annual visit.
All study procedures were carried out by healthcare staff trained 
in the respective fields and guided by standard operating procedures.
2.3 | Outcomes
Recent reported wheeze, eczema and rhinitis were ascertained using 
the International Study on Allergy and Asthma in Children (ISAAC) 
questionnaire,10 with supplementary questions for urticaria. Reported 
wheeze and eczema (a recurrent itchy rash with typical flexural distri-
bution) were classified according to responses from mothers on behalf 
of their children; “recent” was defined as within 12 months.
Visible flexural dermatitis was defined as described by Williams 
et al, and all clinicians were trained using the available online tool.11
Doctor- diagnosed asthma and eczema were established by doc-
tors or clinical officers at either routine or illness visits.
Atopy (SPT): SPT was performed using standard procedures.12 
Allergens tested were Dermatophagoides, Blomia tropicalis, German 
cockroach, cat, mould, grass pollen, Bermuda grass and peanut (ALK- 
Abelló, Laboratory Specialities (Pty) Ltd, Randburg, South Africa). A 
test was classified as positive for an allergen if there is a papule of 
average size >3 mm (while the saline negative control was negative) 
and negative if there is no papule or a papule of average size <3 mm 
(while the histamine positive control was positive).
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Atopy (Allergen- specific IgE specific to Dermatophagoides mixture 
and German cockroach [Blatella germanica]) was measured as previously 
described.5 Samples were considered positive if results were above 
the limit of detection, 312.5 ng/mL.
Forced expiratory volume in one- second (FEV1) was measured 
using a hand- held spirometer (Micro 1 Diagnostic Spirometer, 
CareFusion, Chatham Marine, UK). The best result of three forced ex-
pirations was recorded.
2.4 | Statistical considerations and analysis
The analysis aimed to determine the impact of each treatment (mater-
nal albendazole, maternal praziquantel, infant albendazole) on allergy- 
related outcomes between age 5 and 9 years. Based on our factorial 
study design, our primary analysis for each of these three treatments 
was “everyone who received a particular treatment” vs “everyone 
who did not receive that treatment.” All children who attended at 
9 years were included in the analysis with the exception of children 
from multiple births, in which case just the first- born child was in-
cluded. Additionally, children who attended previous annual visits or 
were seen by a doctor between the ages of five and nine were in-
cluded in the analysis of rates of asthma and eczema.
The primary outcomes were reported wheeze in the last 
12 months, SPT positivity to one or more allergens, and detectable 
asIgE at 9 years. We also analysed individual SPT results, recent re-
ported rhinitis and urticaria at 9 years of age and doctor- diagnosed 
rates of asthma and eczema between the ages of five and nine. We 
included each reported asthma and eczema diagnosis, with the excep-
tion of diagnoses which occurred with 2 weeks of each other, which 
were considered the same event and were recorded with the earliest 
date.
We expected that 1000 children would be seen at 9 years with 
reported wheeze 10%- 15%, and SPT positivity and IgE prevalence ap-
proximately 30%, giving 80% power with P < .05 to detect a difference 
between trial arms of 6% in the proportion of children with wheeze 
and 9% in the proportion with positive SPT or positive asIgE.
All outcomes were assessed using regression models (logistic for 
binary outcomes, linear for continuous measurements, Poisson for 
rates), which included all randomized treatments but no other factors. 
Confounding with maternal hookworm and schistosomiasis was ex-
amined for primary outcomes. The Poisson model included gamma 
distributed random effects to account for clustering of allergy events 
by infant. Additional, pre- planned, analyses were performed in two 
subgroups. We investigated the effect of maternal albendazole on 
children of mothers with and without hookworm and the effect of ma-
ternal praziquantel on children of mothers with and without schistoso-
miasis. These analyses were carried out by introducing an interaction 
term between variables representing the randomized treatment and 
the worm infection in each regression model described above. To ac-
count for multiple comparisons, 99% confidence intervals are reported 
throughout.
3  | RESULTS
A total of 2507 pregnant women were recruited. This analysis in-
cludes only children seen at the 9- year- old annual visit. Excluding 
13 second- born twins and 13 children who were not randomized 
to the intervention in childhood, we had data on 1188 (47.2%) 
mother- child pairs who had received all three randomized treat-
ments (Figure 1). Compared to mothers whose children did not 
attend the 9- year visit, mothers of children included in this article 
F IGURE  1 CONSORT flow diagram
     |  787NAMARA et Al.
T
A
B
L
E
 1
 
Ba
se
lin
e 
ch
ar
ac
te
ris
tic
s
Ch
ar
ac
te
ris
tic
To
ta
l (
n 
= 
11
88
)
M
ot
he
r r
ec
ei
ve
d 
al
be
nd
az
ol
e 
(n
 =
 5
84
)
M
ot
he
r r
ec
ei
ve
d 
pl
ac
eb
o 
(n
 =
 6
04
)
M
ot
he
r r
ec
ei
ve
d 
pr
az
iq
ua
nt
el
 (n
 =
 5
88
)
M
ot
he
r r
ec
ei
ve
d 
pl
ac
eb
o 
(n
 =
 6
00
)
C
hi
ld
 re
ce
iv
ed
 
al
be
nd
az
ol
e 
(n
 =
 5
90
)
C
hi
ld
 re
ce
iv
ed
 
pl
ac
eb
o 
(n
 =
 5
98
)
M
at
er
na
l c
ha
ra
ct
er
is
ti
cs
 (p
ri
or
 to
 in
te
rv
en
ti
on
s 
gi
ve
n 
du
ri
ng
 p
re
gn
an
cy
)
M
at
er
na
l a
ge
 g
ro
up
 (%
)
14
- 1
9
24
1 
(2
0.
3)
12
5 
(2
0.
7)
11
6 
(1
9.
9)
12
3 
(2
0.
5)
11
8 
(2
0.
1)
12
1 
(2
0.
2)
12
0 
(2
0.
3)
20
- 2
4
44
3 
(3
7.
3)
23
4 
(3
8.
7)
20
9 
(3
5.
8)
23
7 
(3
9.
5)
20
6 
(3
5.
0)
22
0 
(3
6.
8)
22
3 
(3
7.
8)
25
- 2
9
28
6 
(2
4.
1)
13
4 
(2
2.
2)
15
2 
(2
6.
0)
13
2 
(2
2.
0)
15
4 
(2
6.
2)
15
3 
(2
5.
6)
13
3 
(2
2.
5)
30
- 3
4
14
2 
(1
2.
0)
73
 (1
2.
1)
69
 (1
1.
8)
68
 (1
1.
3)
74
 (1
2.
6)
71
 (1
1.
9)
71
 (1
2.
0)
35
+
76
 (6
.4
)
38
 (6
.3
)
38
 (6
.5
)
40
 (6
.7
)
36
 (6
.1
)
33
 (5
.5
)
43
 (7
.3
)
M
at
er
na
l e
du
ca
tio
n 
(%
)
N
on
e
27
 (2
.3
)
14
 (2
.3
)
13
 (2
.2
)
14
 (2
.3
)
13
 (2
.2
)
14
 (2
.3
)
13
 (2
.2
)
Pr
im
ar
y
59
3 
(5
0.
0)
30
0 
(4
9.
8)
29
3 
(5
0.
2)
29
9 
(4
9.
8)
29
4 
(5
0.
1)
28
8 
(4
8.
2)
30
5 
(5
1.
8)
Se
ni
or
45
5 
(3
8.
3)
22
6 
(3
7.
5)
22
9 
(3
9.
2)
23
9 
(3
9.
8)
21
6 
(3
6.
8)
24
4 
(4
0.
8)
21
1 
(3
5.
8)
Te
rt
ia
ry
11
2 
(9
.4
)
63
 (1
0.
4)
49
 (8
.4
)
48
 (8
.0
)
64
 (1
0.
9)
52
 (8
.7
)
60
 (1
0.
2)
M
at
er
na
l t
rib
e 
(%
)
M
ug
an
da
65
6 
(5
5.
2)
34
1 
(5
6.
5)
31
5 
(5
3.
9)
32
7 
(5
4.
5)
32
9 
(5
6.
0)
34
2 
(5
7.
2)
31
4 
(5
3.
2)
M
un
ya
nk
ol
e
99
 (8
.3
)
40
 (6
.6
)
59
 (1
0.
1)
57
 (9
.5
)
42
 (7
.1
)
49
 (8
.2
)
50
 (8
.5
)
M
ut
or
o
46
 (3
.9
)
28
 (4
.6
)
18
 (3
.1
)
22
 (3
.7
)
24
 (4
.1
)
26
 (4
.3
)
20
 (3
.4
)
M
us
og
a
41
 (3
.5
)
18
 (3
.0
)
23
 (3
.9
)
19
 (3
.2
)
22
 (3
.7
)
17
 (2
.8
)
24
 (4
.1
)
Lu
o
58
 (4
.9
)
34
 (5
.6
)
24
 (4
.1
)
30
 (5
.0
)
28
 (4
.8
)
25
 (4
.2
)
33
 (5
.6
)
M
un
ya
rw
an
da
54
 (4
.5
)
27
 (4
.5
)
27
 (4
.6
)
28
 (4
.7
)
26
 (4
.4
)
22
 (3
.7
)
32
 (5
.4
)
O
th
er
23
4 
(1
9.
7)
11
6 
(1
9.
2)
11
8 
(2
0.
2)
11
7 
(1
9.
5)
11
7 
(1
9.
9)
11
7 
(1
9.
6)
11
7 
(1
9.
8)
H
ou
se
ho
ld
 s
oc
io
ec
on
om
ic
 s
ta
tu
s 
(%
)
1 
lo
w
es
t
70
 (6
.0
)
39
 (6
.6
)
31
 (5
.4
)
35
 (5
.9
)
35
 (6
.0
)
24
 (4
.1
)
46
 (7
.9
)
2
81
 (6
.9
)
38
 (6
.4
)
43
 (7
.4
)
42
 (7
.1
)
39
 (6
.7
)
40
 (6
.8
)
41
 (7
.1
)
3
34
1 
(2
9.
1)
17
8 
(3
0.
0)
16
3 
(2
8.
2)
17
0 
(2
8.
7)
17
1 
(2
9.
5)
19
2 
(3
2.
4)
14
9 
(2
5.
7)
4
34
8 
(2
9.
7)
17
9 
(3
0.
2)
16
9 
(2
9.
2)
17
3 
(2
9.
2)
17
5 
(3
0.
2)
16
6 
(2
8.
0)
18
2 
(3
1.
4)
5
25
2 
(2
1.
5)
12
1 
(2
0.
4)
13
1 
(2
2.
7)
13
3 
(2
2.
5)
11
9 
(2
0.
6)
13
1 
(2
2.
1)
12
1 
(2
0.
9)
6 
hi
gh
es
t
79
 (6
.7
)
38
 (6
.4
)
41
 (7
.1
)
39
 (6
.6
)
40
 (6
.9
)
39
 (6
.6
)
40
 (6
.9
)
M
at
er
na
l g
ra
vi
di
ty
 (%
)
1
26
9 
(2
2.
6)
12
7 
(2
1.
0)
14
2 
(2
4.
3)
14
6 
(2
4.
3)
12
3 
(2
0.
9)
13
5 
(2
2.
6)
13
4 
(2
2.
7)
2-
 4
68
9 
(5
8.
0)
36
2 
(5
9.
9)
32
7 
(5
6.
0)
34
4 
(5
7.
3)
34
5 
(5
8.
7)
35
0 
(5
8.
5)
33
9 
(5
7.
5)
≥5
23
0 
(1
9.
4)
11
5 
(1
9.
0)
11
5 
(1
9.
7)
11
0 
(1
8.
3)
12
0 
(2
0.
4)
11
3 
(1
8.
9)
11
7 
(1
9.
8) (C
on
tin
ue
s)
788  |     NAMARA et Al.
were older (mean age 24.4 vs 23.0 years), more likely to be Baganda 
(the tribe traditionally based in central Uganda; 55.2% vs 45.4%), 
multiparous (30.4% vs 22.6%) and to belong to a household with 
high social- economic status (58.0% vs 49.5% in class 4 or higher on 
a six- point scale).
Due to the (2 × 2)×2 structure of the trial, there were eight possi-
ble treatment combinations. The most notable difference in baseline 
characteristics was in maternal hookworm infection within the infant 
albendazole randomization (38.9% in active treatment vs 46.1% in pla-
cebo; Table 1).
At age nine, prevalence of nematodes was slightly lower in children 
who had been treated with albendazole quarterly to age five, but the 
prevalence of helminths was low, with the exception of schistosomi-
asis (Table 2).
3.1 | Primary outcomes
At age 9 years, data were available on recent reported wheeze for 
1143 (96.2%) children, SPT allergen response for 1140 (96.0%) and 
allergen- specific IgE response for 1096 (92.3%). The overall preva-
lence of recent reported wheeze was 3.85%, of SPT positivity 25.0% 
and of detectable IgE to house dust mite, cockroach or both 44.1%. 
There was no evidence of an effect of randomized treatment on any 
primary outcome (Table 3). There was no evidence of confounding or 
of any interaction between treatments (P > .1 for all interactions).
In pre- planned subgroup analyses, we also found no evidence of 
an interaction between maternal hookworm and maternal albendazole 
nor maternal schistosomiasis and praziquantel (Table 4).
3.2 | Secondary outcomes
We had data on doctor- diagnosed illness events between ages five 
and nine for 1679 children. Twenty of these experienced a total of 50 
doctor- diagnosed asthma events, a rate of 8.5 per 1000 years of fol-
low- up, giving limited statistical power. There was no clear evidence 
of any effect of treatment on this outcome.
FEV1 measurements were available for 1007 infants (84.8%). The 
mean FEV1 was 1.41 mL (SD = 0.25), with a range of 0.68- 2.5. There 
was no evidence of an effect of treatment on FEV1 (Table 5).
Thirty- eight infants experienced a total of 65 doctor- diagnosed 
eczema events, a rate of 11.0 per 1000 years. There were 58 infants 
with reported eczema in the 12 months prior to their 9- year assess-
ment, but only 29 cases of flexural dermatitis (eczema) discovered 
at examination at 9- year assessments, six of which were related to 
skin lesions in the finger webs indicative of scabies burrows and so 
were not classified as flexural dermatitis according to our protocol. 
Maternal albendazole was associated with a twofold increase in re-
ported eczema, but the confidence interval was wide (OR 2.03; 99% 
CI 0.98, 4.21). OR point estimates were >1.00 for effects of maternal 
and childhood treatment on other measures of eczema, but again con-
fidence intervals were wide.
There were 52 (4.7%) children with recent rhinitis at age nine. There 
was some evidence of a deleterious effect of maternal praziquantel on C
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rhinitis (OR 2.17; 99% CI 1.00- 4.72), but no evidence of any other 
effect of randomized treatment on this outcome.
The most common SPT positives were to Dermatophagoides (207, 
18.3%), Blomia (173, 15.4%) and German cockroach (123, 10.9%). 
There was no evidence of any treatment effect on these SPT re-
sponses. There were insufficient positives to other allergens to draw 
firm conclusions.
4  | DISCUSSION
This trial is the first to investigate effects of anthelminthic intervention 
during pregnancy and early childhood on allergy- related outcomes at 
school age. We found no statistically significant effect—importantly 
no adverse effect—of maternal albendazole or praziquantel treatment 
during pregnancy, or of early- childhood treatment with albendazole, 
on the primary outcomes of wheeze in the last 12 months, or SPT 
response, at age 9 years.
As we have previously reported, our trial interventions during 
pregnancy had a substantial impact on helminth prevalence among 
mothers (albendazole treatment reduced hookworm infection (the 
commonest nematode) to 5%, compared to 45%; praziquantel re-
duced maternal S. mansoni infection to 5% compared with 21%13) and 
there were striking effects of maternal treatment on the incidence of 
infantile eczema: increases of the order of twofold.5 Therefore, we 
seemed well placed to investigate whether these effects translated 
to an impact on allergy- related outcomes at school age. However, we 
encountered a key limitation in the lower- than- expected prevalence 
of wheeze and incidence of doctor- diagnosed asthma: recent wheeze 
was reported by 4% (compared to the predicted 10%- 15%, based on 
previous studies in Ethiopia and Kenya14). No formal testing of air-
way resistance in response to methacholine was done to contribute 
to the diagnosis of asthma. Loss to follow- up made the cohort less 
representative of the Entebbe population than at the outset, but those 
retained were of higher SES than those who were lost, perhaps making 
underestimation of wheeze less likely. Non- atopic triggers for wheeze 
may be less common in Entebbe than elsewhere in Africa; for example, 
moderate temperatures and high humidity are likely to reduce risk of 
exercise- induced wheeze.15 Education of the cohort on ARD may have 
resulted in a better understanding of wheeze and asthma than is usual 
in similar settings, making “false- positive” reports less likely.
We hypothesized that prenatal and early- life treatment of hel-
minths might increase the risk of asthma and wheeze. No such ef-
fect was observed. If anything, there was a possible reduction among 
children exposed to prenatal or early- childhood albendazole. Although 
weak effects, these accord with findings of Lynch and colleagues16 
who found that albendazole treatment reduced rates of asthma in a 
Venezuela cohort. Theoretically, this benefit might represent the ef-
fect of a reduced burden of helminths, such as Ascaris, which induce 
wheeze during migration through the lungs, but the low burden of such 
nematode infections in our cohort makes this explanation unlikely.
Eczema was also uncommon at age nine, as expected with increas-
ing age. Eczema was measured in three ways, all of which gave point 
estimates for effects of treatment that were greater than one but, 
again, there was limited statistical power. These results are in keeping 
with the persistent effect of maternal albendazole treatment observed 
at age five17 and with the observation that eczema in early life was 
associated with eczema at age 9 years in this cohort (Lule et al, under 
review, Ped Allergy Immunol). In addition, there was a suggestion of 
TABLE  2 Worm prevalence at 9- year visit by infant 
randomization group
Species Placebo (n = 597)a (%)
Albendazole 
(n = 589)a (%)
Trichuris 24 (4.02) 21 (3.57)
Ascaris 6 (1.01) 2 (0.34)
Schistosomiasis 64 (10.72) 72 (12.22)
Hookworm 6 (1.01) 0
Trichostrongylus 0 0
Other 13 (2.18)b 7 (1.19)c
aStool samples were unavailable for one infant in each randomization 
group.
bOther species were Hymenolepis nana (10 cases), Enterobius vermicularis.3
cOther species were Hymenolepis nana,5 Enterobius vermicularis.3 One child 
was infected with both species.
TABLE  3 Primary outcomes by randomization group
Outcome
Maternal randomizations Infant randomization
Placebo Albendazole Placebo Praziquantel Placebo Albendazole
Wheeze (last 12 mo) 
Odds ratio (99% CI)
26/580 (4.5%) 18/563 (3.2%) 18/583 (3.1%) 26/560 (4.6%) 22/572 (3.8%) 22/571 (3.9%)
0.70 (0.31- 1.57) 1.53 (0.69- 3.43) 1.01 (0.46- 2.23)
Positive for any SPTa 
Odds ratio (99% CI)
146/576 (25.3%) 139/564 (24.6%) 138/578 (23.9%) 147/562 (26.2%) 144/577 (25.0%) 141/563 (25.0%)
0.96 (0.68- 1.37) 1.13 (0.79- 1.61) 1.00 (0.71- 1.43)
Allergen- specific IgE 
positive to dust or 
cockroach 
Odds ratio (99% CI)
239/557 (42.9%) 244/539 (45.3%) 233/556 (41.9%) 250/540 (46.3%) 242/559 (43.3%) 241/537 (44.9%)
1.10 (0.80- 1.51) 1.20 (0.87- 1.64) 1.07 (0.78- 1.46)
aAny of Blomia tropicalis, Dermatophagoides, cockroach, mould, pollens, Bermuda grass, peanut.
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TABLE  5 Secondary outcomes in different randomization groups
Outcomea
Maternal randomizations Infant randomization
Placebo Albendazole Placebo Praziquantel Placebo Albendazole
Doctor- diagnosed asthma; 
events (individuals)
41 (14) 9 (6) 24 (9) 26 (11) 33 (12) 17 (8)
Hazard ratio (99% CI) 0.26 (0.05- 1.31) 1.01 (0.20- 4.98) 0.54 (0.11- 2.69)
FEV1; mean (SD; n) 1.42 (0.24; 509) 1.40 (0.25; 498) 1.41 (0.24; 513) 1.40 (0.25; 494) 1.41 (0.25; 511) 1.41 (0.25; 496)
Mean difference (99% CI) −0.02 (−0.06, 0.02) −0.01 (−0.05, 0.03) 0.00 (−0.04, 0.04)
Doctor- diagnosed eczema; 
events (individuals)
30 (13) 35 (25) 29 (22) 36 (16) 23 (20) 42 (18)
Hazard ratio (99% CI) 1.25 (0.44- 3.59) 1.27 (0.43- 3.74) 1.78 (0.61- 5.20)
Recent reported eczema (%) 20/604 (3.31) 38/584 (6.51) 25/600 (4.17) 33/588 (5.61) 29/598 (4.85) 29/590 (4.92)
Odds ratio (99% CI) 2.03 (0.98, 4.21) 1.37 (0.68, 2.77) 1.01 (0.51, 2.03)
Visible flexural eczema at 
9 y (%)
10/604 (1.66) 13/584 (2.23) 9/600 (1.50) 14/588 (2.38) 11/598 (1.84) 12/590 (2.03)
Odds ratio (99% CI) 1.35 (0.45, 4.04) 1.60 (0.53, 4.87) 1.11 (0.38, 3.30)
Recent reported rhinitis (%) 28/564 (5.0) 24/552 (4.3) 17/563 (3.0) 35/553 (6.3) 26/563 (4.6) 26/553 (4.7)
Odds ratio (99% CI) 0.87 (0.42- 1.82) 2.17 (1.00- 4.72) 1.03 (0.49- 2.15)
Recent reported urticaria 
(%)
88/583 (15.1) 88/558 (15.8) 88/578 (15.2) 88/563 (15.6) 93/574 (16.2) 83/567 (14.6)
Odds ratio (99% CI) 1.05 (0.69- 1.61) 1.03 (0.68- 1.57) 0.89 (0.58- 1.35)
Dermatophagoides SPT 
positive (%)
103/573 (18.0) 104/559 (18.6) 109/571 (19.1) 98/561 (17.5) 105/573 (18.3) 102/559 (18.2)
Odds ratio (99% CI) 1.04 (0.70- 1.55) 0.90 (0.60- 1.33) 0.99 (0.67- 1.48)
Blomia tropicalis SPT 
positive (%)
90/570 (15.8) 83/556 (14.9) 80/566 (14.1) 93/560 (16.6) 87/571 (15.2) 86/555 (15.5)
Odds ratio (99% CI) 0.93 (0.61- 1.43) 1.21 (0.79- 1.86) 1.02 (0.67- 1.56)
German cockroach SPT 
positive (%)
61/573 (10.6) 62/558 (11.1) 57/569 (10.0) 66/562 (11.7) 65/572 (11.4) 58/559 (10.4)
Odds ratio (99% CI) 1.05 (0.64- 1.71) 1.19 (0.73- 1.96) 0.90 (0.55- 1.48)
Cat SPT positive (%) 7/570 (1.2) 4/556 (0.7) 3/567 (0.5) 8/559 (1.4) 3/568 (0.5) 8/558 (1.4)
Odds ratio (99% CI) 0.58 (0.11- 2.97) 2.72 (0.47- 15.69) 2.71 (0.47- 15.64)
Mould SPT positive (%) 2/571 (0.4) 1/555 (0.2) 0/565 (0.0) 3/561 (0.5) 0/570 (0.0) 3/556 (0.5)
Odds ratio (99% CI) 0.54 (0.02- 12.90) – –
Pollens SPT positive (%) 4/572 (0.7) 8/556 (1.4) 6/568 (1.1) 6/560 (1.1) 5/571 (0.9) 7/557 (1.3
Odds ratio (99% CI) 2.07 (0.42- 10.10) 1.01 (0.23- 4.53) 1.44 (0.32- 6.55)
Bermuda grass SPT positive 
(%)
7/573 (1.2) 7/557 (1.3) 7/568 (1.2) 7/562 (1.2) 4/573 (0.7) 10/557 (1.8
Odds ratio (99% CI) 1.02 (0.26- 4.10) 1.01 (0.25- 4.05) 2.60 (0.56- 12.03)
Peanut SPT positive (%) 6/573 (1.0) 9/557 (1.6) 7/568 (1.2) 8/562 (1.4) 5/572 (0.9) 10/558 (1.8)
Odds ratio (99% CI) 1.55 (0.39- 6.09) 1.16 (0.30- 4.44) 2.07 (0.50- 8.56)
House Dust Mite IgE 
positive (%)
159/557 (28.5) 165/539 (30.6) 158/556 (28.4) 166/540 (30.7) 161/559 (28.8) 163/537 (30.4)
Odds ratio (99% CI) 1.10 (0.78- 1.55) 1.12 (0.80- 1.58) 1.08 (0.77- 1.52)
Cockroach IgE positive (%) 173/557 (31.1) 182/539 (33.8) 170/556 (30.6) 185/540 (34.3) 176/559 (31.5) 179/537 (33.3)
Odds ratio (99% CI) 1.13 (0.81- 1.58) 1.19 (0.85- 1.66) 1.09 (0.78- 1.52)
aThe results given are number of children with the characteristic/number tested (%) unless otherwise specified.
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an adverse effect of maternal albendazole treatment on prevalence of 
rhinitis in 9- year- olds. Thus, for ARD other than wheeze, our findings 
are consistent with a persistent, weak, adverse effect of the early- life 
interventions, but are inconclusive.
By contrast, the prevalence of SPT positivity and detectable asIgE 
was approximately as expected, and hence, we had good power to 
show that the prenatal and early- childhood interventions had no  effect 
on atopy at age 9 years. This implies that possible effects of helminths 
are not mediated by a reduction in the specific IgE response to aller-
gens. Indeed, within this cohort and elsewhere, it has been shown 
that in the presence of helminths, the link between asIgE and ARD 
is suppressed18 and, similarly, the link between asIgE and histamine 
release.19
Evaluation of the time course of ARD in this cohort showed a high 
prevalence and incidence of eczema in infancy but a marked decline 
in ARD with age, and no significant emergence of asthma at school 
age.20 By contrast, the prevalence of atopy increased. This further 
emphasizes the dissociation between atopy and ARD. Given the mod-
est prevalence of helminth infection to age 9 years in this semi- urban 
cohort, we postulate that other exposures also contribute to protec-
tion against allergy- related disease in this environment. Prenatal and 
early- life intervention against helminths, in the absence of change in 
other exposures, is not likely to have any immediate adverse impact 
on allergy- related disease risk in tropical, low- income settings.
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